CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Barcelona, Spain and 89 other locations
multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma...
Phase 2
Barcelona, Spain and 16 other locations
patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...
Phase 1
Barcelona, Spain and 13 other locations
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have e...
Phase 1
Barcelona, Spain and 31 other locations
Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...
Phase 3
Barcelona, Catalunya, Spain and 66 other locations
1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for whic...
Phase 1, Phase 2
Barcelona, Spain and 3 other locations
on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...
Phase 3
Barcelona, Spain and 117 other locations
pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma...
Phase 1
Badalona, Spain and 12 other locations
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....
Phase 1, Phase 2
Barcelona, Spain and 59 other locations
dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...
Phase 1, Phase 2
Barcelona, Spain and 60 other locations
Clinical trials
Research sites
Resources
Legal